Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database

Feng Huang,Xiao San,Qingqian Liu,Haohao Zhu,Wenrong Xu

DOI: https://doi.org/10.1038/s41598-024-57909-y

IF: 4.6

2024-03-30

Scientific Reports

Abstract:This study aims to evaluate the safety of Alprazolam by analyzing the FAERS database, provide data analysis for monitoring adverse drug reactions. This research encompasses adverse event (AE) reports related to Alprazolam from the first quarter of 2004 to the second quarter of 2023. Four signal mining and analysis methods were utilized, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM). Further exploration was conducted regarding patient characteristics and types of AEs. A total of 23,575 AE reports in which Alprazolam was the primary suspect drug were collected, identifying 347 Preferred Term (PT) signals and 27 System Organ Classes (SOCs). The number of AE reports increased annually, especially in 2015, 2018, 2019, and 2020. The main affected groups were females and the age range of 18 to 45. Psychiatric disorders, Nervous system disorders, and Gastrointestinal disorders were the most common the organ system in which the AEs occurred. There is a certain risk of drug abuse and suicide with Alprazolam. Most notably, several AEs not recorded in the Alprazolam leaflet appeared among the top 30 PTs in signal strength, including but not limited to Benzodiazepine drug level abnormal, Acquired amegakaryocytic thrombocytopenia, Cutaneous T-cell dyscrasia, and Coronary No-reflow Phenomenon. For the first time, AEs related to the cardiovascular system and platelet function were unveiled. The severe AE reports that resulted in "hospitalization" and "death" accounted for 30.96% and 21.86%. This study highlights the risks of suicide and misuse of Alprazolam. Other potential severe or fatal AEs, such as those related to the cardiovascular system, platelet function, and others, require further research to determine their precise mechanisms and risk factors.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the safety of Alprazolam and, by analyzing the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, provide data analysis on monitoring adverse drug reactions. Specifically, the study covered adverse event (AE) reports related to Alprazolam from the first quarter of 2004 to the second quarter of 2023, using four signal mining and analysis methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM), and further explored patient characteristics and types of adverse events. ### Research Background Alprazolam is a commonly used intermediate - acting benzodiazepine drug, which mainly inhibits the excitability of the central nervous system by enhancing the inhibitory neurotransmitter γ - aminobutyric acid (GABA) system. It is widely used in clinical practice due to its significant anti - anxiety effect, rapid onset, and effective treatment of insomnia. However, the wide clinical use of Alprazolam is also accompanied by a series of adverse events and potential risks, such as cognitive decline, increased risks of Alzheimer's disease, stroke, and malignant brain tumors, as well as abuse and withdrawal syndromes. ### Research Objectives 1. **Evaluate the safety of Alprazolam**: Identify adverse event signals and risk factors of Alprazolam by analyzing adverse event reports in the FAERS database. 2. **Provide data support**: Provide data support for monitoring adverse drug reactions and help medical professionals better understand and manage the risks of Alprazolam. ### Main Findings - **The number of adverse event reports has increased year by year**: In particular, the number of adverse event reports increased significantly in 2015, 2018, 2019, and 2020. - **The mainly affected groups**: Females accounted for 56.53%, and patients aged between 18 and 45 accounted for 27.86%. - **The most common adverse events**: Mental disorders, neurological disorders, and gastrointestinal disorders are the most common organ - system adverse events. - **Serious adverse events**: Hospitalization and death accounted for 30.96% and 21.86% respectively. - **Newly discovered adverse reactions**: Including abnormal benzodiazepine drug levels, acquired amegakaryocytic thrombocytopenia, cutaneous T - cell hyperplasia, and coronary no - reflow phenomenon, etc. ### Conclusion This study reveals some serious adverse events that may be caused by Alprazolam during use, especially the risks of suicide and abuse. In addition, new adverse reactions related to the cardiovascular system and platelet function have been discovered, and these findings require further research to determine their specific mechanisms and risk factors. This provides important data support for the risk management and clinical practice of Alprazolam.

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database

Risk of Suicide Attempts and Intentional Self-Harm on Alprazolam

Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database

Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database

Data mining and safety analysis of dual orexin receptor antagonists (DORAs): a real-world pharmacovigilance study based on the FAERS database

Mining and analysis of security alert signals of valbenazine based on the Food and Drug Administration Adverse Event Reporting System database

Development of a drug risk analysis and assessment system and its application in signal excavation and analysis of 263 cases of fluoroquinolone-induced adverse reactions

Safety assessment of asenapine in the FAERS database: real adverse event analysis and discussion on neurological and psychiatric side effects

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database

A real-world pharmacovigilance study of esketamine nasal spray

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database

Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System

Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system

Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database

Safety profile of clobazam in the real world: an analysis of FAERS database and systematic review of case reports

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database

Multidimensional assessment of adverse events of bupropion: A large-scale data analysis from the FAERS database

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)